Related Experiment Video
Updated: May 13, 2026

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method
Published on: October 23, 2018
Rapalogs and mTOR inhibitors as anti-aging therapeutics
Dudley W Lamming1, Lan Ye, David M Sabatini
1Whitehead Institute for Biomedical Research, Department of Biology, Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Abstract:
Rapamycin, an inhibitor of mechanistic target of rapamycin (mTOR), has the strongest experimental support to date as a potential anti-aging therapeutic in mammals. Unlike many other compounds that have been claimed to influence longevity, rapamycin has been repeatedly tested in long-lived, genetically heterogeneous mice, in which it extends both mean and maximum life spans. However, the mechanism that accounts for these effects is far from clear, and a growing list of side effects make it doubtful that rapamycin would ultimately be beneficial in humans. This Review discusses the prospects for developing newer, safer anti-aging therapies based on analogs of rapamycin (termed rapalogs) or other approaches targeting mTOR signaling.
Insights
Rapamycin shows promise for anti-aging in mammals by extending lifespan. However, its unclear mechanisms and side effects necessitate developing safer mTOR-targeting therapies like rapalogs.
Area of Science:
- Gerontology and aging research
- Pharmacology and drug discovery
- Molecular biology and signaling pathways
Background:
- Rapamycin, an inhibitor of mechanistic target of rapamycin (mTOR), is a leading candidate for anti-aging therapies.
- It has demonstrated lifespan extension in genetically heterogeneous mice, a robust model for aging studies.
- Despite its efficacy, the precise mechanisms of action and potential side effects in humans remain significant concerns.
Purpose of the Study:
- To review the current evidence supporting rapamycin as an anti-aging therapeutic.
- To discuss the limitations and side effects associated with rapamycin treatment.
- To explore future directions in developing safer mTOR-targeting anti-aging strategies.
Main Methods:
- Review of existing scientific literature on rapamycin and mTOR signaling.
- Analysis of experimental data from mammalian aging studies, particularly in mice.
- Evaluation of potential therapeutic strategies based on rapamycin analogs (rapalogs) and other mTOR pathway modulators.
Main Results:
- Rapamycin consistently extends mean and maximum lifespan in long-lived, genetically heterogeneous mice.
- The underlying molecular mechanisms responsible for rapamycin's life-extending effects are not fully elucidated.
- Rapamycin is associated with a notable list of side effects, questioning its direct applicability in human anti-aging interventions.
Conclusions:
- While rapamycin offers strong evidence for anti-aging effects in mammals, its clinical use is limited by safety concerns and unclear mechanisms.
- Future anti-aging therapies should focus on developing rapalogs or alternative mTOR pathway inhibitors with improved safety profiles.
- Targeting mTOR signaling remains a promising avenue for interventions aimed at promoting longevity and healthspan.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
Mitochondria
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Replicative Cell Senescence